Pikkelysömör: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• IL-17 12
• IL-23 6
• STAT3 0
• TNF 5
• JAK 1
• GLP-1 5
• TYK2 1
• PI3K 0
• NLRP3 0
• IL-6 0
• IL-1 0
• AKT 0
• MAPK 0
• PDE4 1
• NRF2 0
• PD-1 0
• PPAR 0
• STING 0
• mTOR 0
• TLR4 0
• AMPK 0
• ERK 0
• GIP 1
• VEGF 0
• MMP-9 0
• PD-L1 0
• COX-2 0
• HIF-1 0
• IL-4 0
• SIRT1 0
• TP53 0
• APOE 0
• CGRP 0
• IL-13 0
• KEAP1 0
• LAG-3 0
• PCSK9 0
• PKM2 0
• SGLT2 0
• TSLP 0
• AR 0
• BCL-2 0
• BDNF 0
• BRD4 0
• CD123 0
• CD19 0
• CD40 0
• CSF1R 0
• CTLA-4 0
• CTNNB1 0
• CXCR4 0
• EGFR 0
• EZH2 0
• FTO 0
• G6PD 0
• GPRC5D 0
• HMGB1 0
• HSP90 0
• IDH 0
• JNK 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Synergistic Nano-Therapeutic Approach for Psoriasis: Targeting TNF-α and IL-17 Pathways via Transdermal Delivery (SKINNOVATE)

  Academisch Ziekenhuis Groningen· Groningen, Hollandia· EU contribution 232 916 EUR· until 2027. okt.

• European Commission (Horizon Europe) · HORIZON-ERC

  Unmasking Non-Genetic Determinants Instructing Tumor Initiation (IGNITE)

  Fundacio Institut de Recerca Biomedica (Irb Barcelona)· Barcelona, Spanyolország· EU contribution 1 995 000 EUR· until 2030. szept.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Positive allosteric modulators of the PD-1•PD-L1 interaction as a new mode of therapeutic intervention for autoimmune diseases: preclinical proof of concept in humanized mice (PAMinMICE)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution 150 000 EUR· until 2027. febr.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Dissolving microneedle array patch-based psoriatic immunotherapy using nanoparticles (MAPiT)

  Stockholms Universitet· Stockholm, Svédország· EU contribution 222 728 EUR· until 2027. febr.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification (Lab-In-Skin)

  Universiteit Twente· Enschede, Hollandia· EU contribution 150 000 EUR· until 2026. dec.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Spatio-temporal integration of skin inflammation (4D-SkINFLAM)

  Deutsches Rheuma Forschungszentrumberlin· Berlin, Németország· EU contribution 2 499 188 EUR· until 2028. szept.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  DNA methylation markers to predict treatment success of biologicals in Crohn’s disease. (METHYLOMIC)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 9 376 995 EUR· until 2026. dec.· 9 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  iPROLEPSIS: PSORIATIC ARTHRITIS INFLAMMATION EXPLAINED THROUGH MULTI-SOURCE DATA ANALYSIS GUIDING A NOVEL PERSONALISED DIGITAL CARE ECOSYSTEM

  Aristotelio Panepistimio Thessalonikis· Thessaloniki, Görögország· EU contribution 6 483 091 EUR· until 2027. dec.· 9 countries

• European Commission (Horizon 2020) · RIA

  Health Initiatives in Psoriasis and PsOriatic arthritis ConsoRTium European States (HIPPOCRATES)

  University College Dublin, National University of Ireland, Dublin· Dublin, Írország· EU contribution 10 210 993 EUR· until 2027. jún.· 11 countries

9 of 9 running projects, newest first. Listed amounts together: 31,3 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial

  NCT07111494· Medical College of Wisconsin· Forrás

• CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

  NCT07567378· JULIO GRANADOS MONTIEL· Forrás

• Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

  NCT07401992· Hospital Universitario Dr. Jose E. Gonzalez· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 28
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 4
• Gene Expression Profiling 66
• Sequence Analysis, RNA 6
• Exome Sequencing 5
• Proteomics 24
• Metabolomics 13
• Flow Cytometry 11
• Immunohistochemistry 24
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 23
• Machine Learning 27
• Deep Learning 4
• Cohort Studies 63
• Genome-Wide Association Study 38

• Identification of plaque psoriasis subgroups based on peripheral blood immune cells subtypes and their relationship with biologic therapy efficacy: a single-center longitudinal cohort study in China.

  Expert Opin Biol Ther, 2026. jún.

• RA and PsA synovial tissue single-cell analysis demonstrates differential fibroblast populations with distinct phenotypes and functional capacities.

  Ann Rheum Dis, 2026. ápr.

• The Level and Clinical Significance of B Lymphocytes and Immune Molecules (IL-4, IL-10, BAFF, and IgD) in Psoriasis.

  Immun Inflamm Dis, 2026. márc.

• Single cell mapping identifies a distinct platelet-phenotype in psoriatic type III inflammation.

  Nat Commun, 2025. dec.

• CD3+ immune cell endotypes are associated with PsA disease phenotype and response to advanced therapy: an integrated mass cytometry and proteomics cohort study.

  Ann Rheum Dis, 2025. nov.

• Cigarette and Cannabis Smoking Effects on GPR15+ Helper T Cell Levels in Peripheral Blood: Relationships with Epigenetic Biomarkers.

  Genes (Basel), 2020. jan.

• Distinctive downmodulation of plasmacytoid dendritic cell functions by vitamin D3 analogue calcipotriol.

  J Dermatol Sci, 2016. jún.

• A left/right comparison of twice-daily calcipotriol ointment and calcitriol ointment in patients with psoriasis: the effect on keratinocyte subpopulations.

  Acta Derm Venereol, 2004. jan.

• Reduction of epidermal abnormalities and inflammatory changes in psoriatic plaques during treatment with vitamin D3 analogs.

  J Investig Dermatol Symp Proc, 1996. ápr.

• Calcitriol and its analog KH 1060 induce similar changes in keratinocyte cell cycle progression after topical application to mouse skin. A bromodeoxyuridine pulse-chase flow cytometric study.

  J Investig Dermatol Symp Proc, 1996. ápr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.